jcm-logo

Journal Browser

Journal Browser

Multimorbidity and Polypharmacy: From Clinical Complexity to Patient Safety

A Special Issue of Journal of Clinical Medicine (ISSN 2077-0383) belonging to the section "Pharmacology".

Deadline for manuscript submissions: 20 October 2026 | Viewed by 1178

Editors


E-Mail Website
Guest Editor
Department of Medical Sciences II—Pharmacology, Clinical Pharmacology and Algesiology, ”Grigore T. Popa” University of Medicine and Pharmacy, 700115 lași, Romania
Interests: arterial stiffness; adherence; antibiotics; stress hormones; clinical pharmacology; experimental pharmacology
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Department of Pharmaceutical Marketing and Management, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
Interests: pharmacology; polypharmacy; adherence; direct-acting antiviral (DAA); hepatitis C; diabetes; pharmaceutical services

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue, “Multimorbidity and Polypharmacy: From Clinical Complexity to Patient Safety.” Multimorbidity, defined as the coexistence of two or more chronic conditions, is increasingly prevalent across all age groups, particularly among older adults. Its management often necessitates polypharmacy, which, while clinically justified, introduces significant risks such as adverse drug events, drug–drug interactions, medication non-adherence, and increased healthcare utilization.

This Special Issue aims to provide a comprehensive and multidisciplinary overview of current evidence, methodological advances, and practical interventions addressing multimorbidity and polypharmacy. This topic aligns closely with the journal’s scope by focusing on clinical medicine, patient safety, and healthcare quality. By fostering a focused yet sufficiently broad collection of contributions, this Special Issue seeks to garner at least 10 high-quality articles that may ultimately be published in book form.

In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the following:

  • Epidemiology and multimorbidity;
  • Appropriate prescribing and deprescribing strategies;
  • Medication safety and adverse drug events;
  • Clinical support and digital health tools.

Prof. Dr. Cristina Ghiciuc
Dr. Mihaela Simona Naidin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multimorbidity
  • polypharmacy
  • patient safety
  • medication management
  • diabetes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 246 KB  
Article
Wise Prescriptions: Prevalence and Predictors of Polypharmacy in Patients with Type 2 Diabetes Mellitus in Primary Care: A Retrospective Cross-Sectional Study
by Mohammed M. Alsultan, Danya R. Al Thani, Sara A. Shwaiheen, Ethabah A. Al Drees, Mohammed A. Al Drees, Reem D. AlQahtani, Amnah A. Alnubi, Shuaa Y. Alali and Amani M. AlQarni
J. Clin. Med. 2026, 15(8), 3002; https://doi.org/10.3390/jcm15083002 - 15 Apr 2026
Viewed by 864
Abstract
Background/Objectives: Diabetes mellitus is a common chronic disease that may lead to multimorbidity and high drug use. Therefore, this study aims to examine the prevalence of polypharmacy and hyperpolypharmacy among adult patients diagnosed with type 2 diabetes mellitus (T2DM) with its associated [...] Read more.
Background/Objectives: Diabetes mellitus is a common chronic disease that may lead to multimorbidity and high drug use. Therefore, this study aims to examine the prevalence of polypharmacy and hyperpolypharmacy among adult patients diagnosed with type 2 diabetes mellitus (T2DM) with its associated factors. Methods: This is a retrospective cross-sectional study conducted from 1 May 2023 to 31 October 2024. The outcomes in our study were polypharmacy (from five to nine drugs) and hyperpolypharmacy (≥10 drugs). Baseline and demographic characteristics, along with multinomial logistic regression, were used to analyze the data. Results: The total number of patients with T2DM was 2435. The prevalence rate of polypharmacy was 46.98%, while hyperpolypharmacy was 24.27%. Older age was significantly associated with a higher risk of polypharmacy [OR = 1.031, 95% (1.022–1.040)] and hyperpolypharmacy [OR = 1.037, 95% (1.026–1.049)]. In addition, patients with higher levels of hemoglobin A1c showed a significantly higher risk of polypharmacy and hyperpolypharmacy ([OR = 1.162, 95% (1.105–1.221)] and [OR = 1.284, 95% (1.209–1.364)], respectively). The comorbidities that increased the odds of hyperpolypharmacy were hypertension [OR = 2.136, 95% (1.449–3.148)], pulmonary disease [OR = 2.375, 95% (1.292–4.367)], mental disorders [OR = 6.269; 95% (3.284–11.964], and congestive heart failure [OR = 8.014, 95% (2.768–23.200)]. Conclusions: The prevalence of polypharmacy and hyperpolypharmacy is high in patients with T2DM. The predictors that may play a significant role in increasing the risk of hyperpolypharmacy are the poor control of HbA1c and the coexistence of comorbidities. Providing proper prescribing of patients’ therapy plans can improve individuals’ health outcomes. Therefore, this study highlights the important role of primary care physicians in coordinating care, along with clinical pharmacists, in the identification of polypharmacy. Full article
Back to TopTop